The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a single arm clinical study to estimate the safety, tolerability and pharmacokinetic
(PK) characteristics of Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109 in
patients with recurrent glioblastoma (r-GBM) and preliminarily evaluate the effectiveness,
the immunogenicity of the product, as well as their correlation between the changes of
cytokines from baseline level after cellular infusion.